2026 Global: Clinical Trial Imaging Market-Competitive Review (2032) report
Description
The 2026 Global: Clinical Trial Imaging Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for clinical trial imaging market by geography and historical trend. The scope of the report extends to sizing of the clinical trial imaging market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
ICON plc, IQVIA, Parexel, Medpace, Clario, Siemens Healthineers, BioClinica, IXICO, Invicro, and MedNet Solutions are among the ten major companies shaping the clinical trial imaging market through integrated imaging services, centralized image reading, quantitative biomarker extraction, and regulatory-ready data packages. ICON leverages global CRO scale and acquisitions to provide imaging core lab services and cardiac safety monitoring across modalities and therapeutic areas. IQVIA couples large clinical operations and real-world evidence capabilities with imaging data integration and analytics to support endpoint qualification and site selection in multicenter trials. Parexel offers regulatory expertise and imaging trial design support alongside imaging read services and has been identified as a top CRO with imaging capabilities in market analyses. Medpace operates a dedicated Core Lab and imaging services aligned to oncology and cardiology programs, delivering centralized reads, QA, and quantitative image analysis for global studies. Clario provides eClinical platforms plus imaging and safety services focused on data quality, patient safety monitoring, and interoperable imaging workflows for clinical sponsors.
Siemens Healthineers and BioClinica bring strong technology and specialized imaging-read expertise to trials, with Siemens supplying advanced modality systems, software, and vendor partnerships for image standardization and biomarker extraction while BioClinica supplies long-standing central reading, adjudication, and imaging data management services tailored to regulatory submissions. IXICO focuses on neuroimaging, quantitative imaging biomarkers, and AI-enabled analytics for CNS studies, supporting imaging endpoints in Alzheimer’s and other neurodegenerative disease trials through validated pipelines and standardized output. Invicro provides cloud-based image management, quantitative analytics, and biomarker services—combining imaging science, software platforms, and CRO partnerships to accelerate imaging endpoints across PET, MRI, and CT studies. MedNet Solutions (and comparable specialized core labs and imaging vendors) deliver site training, image acquisition QC, DICOM management, and blinded central reads, supporting decentralized acquisition and hybrid trial models that demand robust image traceability and audit-ready datasets.
Collectively these firms address the principal needs of modern imaging-enabled trials—harmonized acquisition across sites, vendor-neutral image transfer, blinded central reads, quantitative biomarker derivation, regulatory compliance, and integrated eClinical interoperability—enabling sponsors to deploy imaging as surrogate or secondary endpoints in oncology, cardiology, neurology, and rare-disease programs. Market reports highlight continued consolidation and strategic acquisitions as companies expand imaging portfolios, add AI/quantitative tools, and integrate modality vendors and cloud platforms to reduce variability, shorten review timelines, and support submission-quality imaging dossiers for global regulatory authorities.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for clinical trial imaging market by geography and historical trend. The scope of the report extends to sizing of the clinical trial imaging market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
ICON plc, IQVIA, Parexel, Medpace, Clario, Siemens Healthineers, BioClinica, IXICO, Invicro, and MedNet Solutions are among the ten major companies shaping the clinical trial imaging market through integrated imaging services, centralized image reading, quantitative biomarker extraction, and regulatory-ready data packages. ICON leverages global CRO scale and acquisitions to provide imaging core lab services and cardiac safety monitoring across modalities and therapeutic areas. IQVIA couples large clinical operations and real-world evidence capabilities with imaging data integration and analytics to support endpoint qualification and site selection in multicenter trials. Parexel offers regulatory expertise and imaging trial design support alongside imaging read services and has been identified as a top CRO with imaging capabilities in market analyses. Medpace operates a dedicated Core Lab and imaging services aligned to oncology and cardiology programs, delivering centralized reads, QA, and quantitative image analysis for global studies. Clario provides eClinical platforms plus imaging and safety services focused on data quality, patient safety monitoring, and interoperable imaging workflows for clinical sponsors.
Siemens Healthineers and BioClinica bring strong technology and specialized imaging-read expertise to trials, with Siemens supplying advanced modality systems, software, and vendor partnerships for image standardization and biomarker extraction while BioClinica supplies long-standing central reading, adjudication, and imaging data management services tailored to regulatory submissions. IXICO focuses on neuroimaging, quantitative imaging biomarkers, and AI-enabled analytics for CNS studies, supporting imaging endpoints in Alzheimer’s and other neurodegenerative disease trials through validated pipelines and standardized output. Invicro provides cloud-based image management, quantitative analytics, and biomarker services—combining imaging science, software platforms, and CRO partnerships to accelerate imaging endpoints across PET, MRI, and CT studies. MedNet Solutions (and comparable specialized core labs and imaging vendors) deliver site training, image acquisition QC, DICOM management, and blinded central reads, supporting decentralized acquisition and hybrid trial models that demand robust image traceability and audit-ready datasets.
Collectively these firms address the principal needs of modern imaging-enabled trials—harmonized acquisition across sites, vendor-neutral image transfer, blinded central reads, quantitative biomarker derivation, regulatory compliance, and integrated eClinical interoperability—enabling sponsors to deploy imaging as surrogate or secondary endpoints in oncology, cardiology, neurology, and rare-disease programs. Market reports highlight continued consolidation and strategic acquisitions as companies expand imaging portfolios, add AI/quantitative tools, and integrate modality vendors and cloud platforms to reduce variability, shorten review timelines, and support submission-quality imaging dossiers for global regulatory authorities.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.